Immuneering (IMRX) Update / Briefing June 17, 2025 08:00 AM ET Speaker0 Welcome to the Immuneering Conference Call to discuss a positive data update from the company's ongoing Phase IIa trial of atebimetinib in first line pancreatic cancer patients. At this time, all participants are in listen only mode. Following management prepared remarks, we will hold a q and a session. To ensure that we have ample time to address everyone's questions, we would ask each person to limit themselves to one question and one ...

Outpacing Cancer to Help Patients Outlive their Disease June 2025 This presentation contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding: Immuneering Corporation's (the "Company") plans to develop, manufacture and commercialize its product candida ...

Immuneering (IMRX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Alright. I think we're good to get started on our next session. So we are, excited to welcome from m n eering, CEO of Minseskind and, Igor Matushanski. Speaker1 Guys, please take it away. Speaker2 Well, great. I want to thank you and the entire Jefferies team for having us today and remind everyone we'll be making forward looking statements so please see our disclosures for more information. So we aim to help cancer patients outlive their ...